Showcases Stock ranks Forex

Cullinan Management Inc (CGEM)
10.51  -0.05 (-0.47%) 03-24 16:00
Open: 10.52 Pre. Close: 10.56
High: 10.68 Low: 10.3
Volume: 142,134 Market Cap: 413(M)
Stock Technical Analysis
Target: Six months: 13.13
One year: 13.82
Support: Support1: 10.30
Support2: 8.57
Resistance: Resistance1: 11.25
Resistance2: 11.83
Pivot: 10.98
Moving Averages: MA(5): 10.66
MA(20): 11.06
MA(100): 11.42
MA(250): 12.04
MACD: MACD(12,26): -0.15
Signal(12,26,9): -0.07
%K %D: %K(14,3): 12.30
%D(3): 20.44
RSI: RSI(14): 41.10
52-Week: High: 15.89
Low: 7.3
Change(%): -5.4
Average Vol(K): 3-Month: 212
10-Days: 386
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 10.705 - 10.758 10.758 - 10.8
Low: 10.156 - 10.227 10.227 - 10.284
Close: 10.41 - 10.518 10.518 - 10.606
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ CGEM ] has closed above bottom band by 10.5%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Stock chart
Stock News
Tue, 14 Mar 2023
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting -

Sun, 12 Mar 2023
Hsbc Holdings PLC Takes Position in Cullinan Oncology, Inc ... - MarketBeat

Sat, 11 Mar 2023
Martingale Asset Management L P Makes New $398000 Investment ... - MarketBeat

Thu, 09 Mar 2023
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results -

Mon, 27 Feb 2023
Cullinan Oncology to Participate in Cowen's 43rd Annual - GlobeNewswire

Mon, 13 Feb 2023
Cullinan Oncology Licenses U.S. Rights to the First - GlobeNewswire

Financial Analysis
Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 39.33
Shares Float (M) 22.78
% Held by Insiders 12.56
% Held by Institutions 81.50
Shares Short (K) 2100
Shares Short Prior Month (K) 1940
Stock Financials
EPS 2.470
Book Value (p.s.) 11.680
Profit Margin
Operating Margin
Return on Assets (ttm) -16.3
Return on Equity (ttm) 22.7
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -3.306
Qtrly Earnings Growth
Operating Cash Flow (M) -126.66
Levered Free Cash Flow (M) -46.35
Stock Valuation
PE Ratio 4.26
PEG Ratio
Price to Book value 0.90
Price to Sales
Price to Cash Flow -3.26
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android